<DOC>
	<DOCNO>NCT02085655</DOCNO>
	<brief_summary>Extranodal natural killer/T-cell lymphoma ( ENKTL ) aggressive form non-Hodgkin 's lymphoma show extremely poor survival . This prospective pilot study evaluate efficacy safety long-acting aspargase ( pegylated aspargase , PEG-ASP ) combine gemcitabine oxaliplatin ( PASP -Gemox ) treatment population .</brief_summary>
	<brief_title>PEG-ASP+Gemox Regimen Thalidomide NK/T Lymphoma</brief_title>
	<detailed_description>Eligibility criteria The eligibility criterion pathologically confirm , previously untreated refractory/relapsed ENKTL define World Health Organization classification ; age≥18 year ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0-2 ; least one measurable lesion ; adequate haematologic function ( haemoglobin &gt; 9.0 g/l , absolute neutrophil count &gt; 1500/ml , platelet &gt; 75,000/l ) , hepatic function ( total serum bilirubin ≤ 1.5 time upper limit normal , alanine aminotransferase aspartate aminotransferase ≤ 2.5 time upper limit normal ) , renal function ( serum creatinine ≤ 1.5 mg/dl , creatinine clearance ≥ 50 ml/min ) ; normal coagulation function electrocardiogram result . Prior chemotherapy radiotherapy complete &gt; 4 week earlier , willingness provide write informed consent . Stage define accord Ann Arbor system . The Sun Yat-Sen University Cancer Centre Research Ethics Board approve study subject enrol . Treatment PA-Gemox dosage follow : day 1 8 , 30-min intravenous infusion 1000 mg/m2 gemcitabine ; day 1 , 2-h intravenous infusion 130 mg/m2 oxaliplatin ; day 1 , deep intramuscular injection 2500 U/m2 PEG-ASP two different site . The regimen repeat every 3 week maximum six cycle . Stage IE/IIE patient underwent four cycle induction chemotherapy , follow involved-field radiotherapy get CR , PR SD . Three-dimensional conformal radiotherapy do linear accelerator 2.0 gray ( Gy ) per daily fraction 5-6 week . The involved- field radiation ( IFRT ) dose 50-56 Gy . Refractory/relapsed patient underwent least two cycle treatment unless disease progression unacceptable side effect , withdrawal patient consent . Autologous haematopoietic stem cell transplantation ( AHSCT ) recommend achieve CR .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>1. pathologically confirm , previously untreated refractory/relapsed ENKTL define World Health Organization classification ; 2. age≥18 year ; 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ; 4. least one measurable lesion ; 5. adequate haematologic function ( haemoglobin &gt; 9.0 g/l , absolute neutrophil count &gt; 1500/ml , platelet &gt; 75,000/l ) , 6. adequate hepatic function ( total serum bilirubin ≤ 1.5 time upper limit normal , alanine aminotransferase aspartate aminotransferase ≤ 2.5 time upper limit normal ) , 7. adequate renal function ( serum creatinine ≤ 1.5 mg/dl , creatinine clearance ≥ 50 ml/min ) ; 8. normal coagulation function electrocardiogram result . 9 . Prior chemotherapy radiotherapy complete &gt; 4 week earlier , 10. willingness provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Extranodal NK/T-cell lymphoma</keyword>
	<keyword>PA-Gemox regimen</keyword>
	<keyword>thalidomide</keyword>
</DOC>